Premium
A stable meta ‐carborane enables the generation of boron‐rich peptide agonists targeting the ghrelin receptor
Author(s) -
Worm Dennis J.,
ElsHeindl Sylvia,
Kellert Martin,
Kuhnert Robert,
Saretz Stefan,
Koebberling Johannes,
Riedl Bernd,
HeyHawkins Evamarie,
BeckSickinger Annette G.
Publication year - 2018
Publication title -
journal of peptide science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 66
eISSN - 1099-1387
pISSN - 1075-2617
DOI - 10.1002/psc.3119
Subject(s) - peptide , chemistry , carborane , receptor , ghrelin , boron , conjugate , agonist , cancer cell , biochemistry , biophysics , pharmacology , cancer research , cancer , medicine , stereochemistry , biology , organic chemistry , mathematical analysis , mathematics
Boron neutron capture therapy (BNCT) is a binary cancer therapy, which combines the biochemical targeting of a boron‐containing drug with the regional localization of radiation treatment. Although the concept of BNCT has been known for decades, the selective delivery of boron into tumor cells remains challenging. G protein‐coupled receptors that are overexpressed on cancer cells in combination with peptidic ligands can be potentially used as shuttle system for a tumor‐directed boron uptake. In this study, we present the generation of short, boron‐rich peptide conjugates that target the ghrelin receptor. Expression of the ghrelin receptor on various cancer cells makes it a viable target for BNCT. We designed a novel hexapeptide super‐agonist that was modified with different specifically synthesized carborane monoclusters and tested for ghrelin receptor activation. A meta ‐carborane building block with a mercaptoacetic acid linker was found to be optimal for peptide modification, owing to its chemical stability and a suitable activation efficacy of the conjugate. The versatility of this carborane for the development of peptidic boron delivery agents was further demonstrated by the generation of highly potent, boron‐loaded conjugates using the backbone of the known ghrelin receptor ligands growth hormone releasing peptide 6 and Ipamorelin.